The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up

详细信息    查看全文

• 作者：Tsung-Hui Hu (1) (4)
  Ming-Chao Tsai (1)
  Yen-Ta Chen (2)
  Yu-Shu Chien (3)
  Chao-Hung Hung (1)
  Te-Chuan Chen (3)
  Po-Lin Tseng (1)
  Kuo-Chin Chang (1)
  Yi-Hao Yen (1)
  
• 关键词：Renal transplantation ; Hepatitis B virus ; Lamivudine ; Roadmap
• 刊名：Hepatology International
• 出版年：2012
• 出版时间：April 2012
• 年：2012
• 卷：6
• 期：2
• 页码：449-456
• 全文大小：290KB
• 参考文献：1. Fabrizi F, Lunghi G, Poordad FF, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol 2002;15:113-22
  2. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:2913-921 CrossRef
  3. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257-63 CrossRef
  4. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001;21:300-06 CrossRef
  5. Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation. Nephron 2002;90:241-51 CrossRef
  6. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996;62:297-99 CrossRef
  7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8 CrossRef
  8. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-263 CrossRef
  9. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-215 CrossRef
  10. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004;77:859-64 CrossRef
  11. Durlik M, Lewandowska D. Lamivudine therapy for chronic hepatitis B in renal transplant recipients. Eur J Gastroenterol Hepatol 2004;16:1261-264 CrossRef
  12. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13 CrossRef
  13. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2 CrossRef
  14. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-395 CrossRef
  15. Gwak GY, Huh W, Lee DH, et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007;39:3121-126 CrossRef
  16. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004;4:1103-109 CrossRef
  17. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-97 CrossRef
  18. Liu CJ, Chen PJ, Lai MY, et al. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int 2006;26:949-55 CrossRef
  19. Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005;43:6000-006 CrossRef
  20. Hung CH, Lu SN, Wang JH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003;38:153-57 CrossRef
  21. Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003;38:95-01 CrossRef
  22. Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999;450:66-1 CrossRef
  23. Harnett JD, Zeldis JB, Parfrey PS, et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987;44:369-76 CrossRef
  24. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991;51:391-96
  25. Han DJ, Kim TH, Park SK, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001;71:387-94 CrossRef
  26. Park SK, Yang WS, Lee YS, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001;16:2222-228 CrossRef
  27. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-252 CrossRef
  28. Thabut D, Thibault V, Bernard-Chabert B, et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004;16:1367-373 CrossRef
  29. Kamar N, Sandres-Saune K, Ribes D, et al. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol 2004;31:298-03 CrossRef
  30. Kletzmayr J, Watschinger B, Muller C, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000;70:1404-407 CrossRef
  31. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-62 CrossRef
  32. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-40
  33. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89 CrossRef
  34. Lok AS. Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better? Gastroenterology 2000;119:263-66 CrossRef
  35. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72 CrossRef
  36. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80 CrossRef
  37. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34 CrossRef
  38. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91 CrossRef
  39. Huang YW, Liu CJ, Lai MY, et al. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: a retrospective case series. Clin Ther 2006;28:1327-334 CrossRef
  40. Tsai MC, Chen CH, Lee CM, et al. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 2009;50:281-88 CrossRef
  41. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005;34:S143–S146 CrossRef
  42. Hashimoto Y, Suzuki F, Hirakawa M, et al. Clinical and virological effects of long-term (over 5?years) lamivudine therapy. J Med Virol 2010;82:684-91 CrossRef
  43. Burger DM, Verweel G, Rakhmanina N, et al. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007;81:517-20 CrossRef
  44. Kawaoka T, Suzuki F, Akuta N, et al. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007;42:395-01 CrossRef
  45. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996;40:1514-519
  46. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-6 CrossRef
  47. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-58 CrossRef
  48. Terrault NA, Tran TT, Schiff E, et al. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. Liver Int 2009;29:1178-183 CrossRef
  
• 作者单位：Tsung-Hui Hu (1) (4)
  Ming-Chao Tsai (1)
  Yen-Ta Chen (2)
  Yu-Shu Chien (3)
  Chao-Hung Hung (1)
  Te-Chuan Chen (3)
  Po-Lin Tseng (1)
  Kuo-Chin Chang (1)
  Yi-Hao Yen (1)
  
  1. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung District, Kaohsiung, 833, Taiwan
  4. Department of Nursing, School of Nursing, Fooyin University, Kaohsiung, Taiwan
  2. Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
  3. Department of Nephrology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
  

文摘

Background Early prediction of lamivudine (LAM) response by individualized monitoring of serum HBV DNA like roadmap concept, and investigation of the outcome after LAM discontinuation in renal transplant recipients (RTRs) with chronic hepatitis B (CHB). Methods We conducted a study on 19 RTRs with HBV infection receiving LAM treatment for 2?years from 2004 to 2007. HBV DNA level was assessed at baseline, 12, 24, 52, and 104?weeks after treatment. Risk factors of tyrosine–methionine–aspartate–aspartate (YMDD) mutation on treatment and relapse rate of HBV after LAM discontinuation were analyzed. Results HBV DNA levels became undetectable in 32, 37, 63, and 53% of patients after 12, 24, 52, and 104?weeks of LAM treatment, respectively. Overall, three (16%) and five (33%) patients were detected with YMDD mutations at week 52 and 104, respectively. In the concept of roadmap, of the seven patients with inadequate virologic response (IAVR) at week 24, five had YMDD mutations. There was no significant association of YMDD mutations with age, gender, genotype, cirrhosis, HBeAg status, baseline HBV DNA, precore/core promoter mutations, and primary response, except IAVR at week 24 (P?=?0.001). The relapse rate of HBV after LAM discontinuation was high (75%) during a median follow-up of 65?weeks. Conclusions The rate of LAM resistance in RTRs is similar to immunocompetent CHB patients in a 2-year therapy. By roadmap concept, RTRs with IAVR require a change in therapy to prevent viral resistance. Relapse after LAM withdrawal is frequent. Long-term antiviral therapy is crucial for immunosuppressed patients.